---
document_datetime: 2025-01-08 16:29:54
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/amsparity-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: amsparity-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.9976047
conversion_datetime: 2025-12-23 01:45:33.439601
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Amsparity

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0009/G            | This was an application for a group of variations. | 07/01/2025                          |                                             | SmPC and PL                      |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |                 |                                                                                                                                                                                                                                                                         |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0012             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                            | 09/12/2024 | n/a        |                 |                                                                                                                                                                                                                                                                         |
| R/0008              | Renewal of the marketing authorisation.                                                                                                                         | 25/07/2024 | 19/09/2024 | SmPC and PL     | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Amsparity in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IAIN/0007           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                      | 12/12/2023 | 19/09/2024 | Annex II and PL |                                                                                                                                                                                                                                                                         |
| PSUSA/10783 /202212 | Periodic Safety Update EU Single assessment - adalimumab                                                                                                        | 31/08/2023 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                       |
| IA/0005             | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                      | 06/07/2022 | n/a        |                 |                                                                                                                                                                                                                                                                         |
| IB/0004             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                   | 23/09/2021 | n/a        |                 |                                                                                                                                                                                                                                                                         |
| IAIN/0003           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                  | 12/07/2021 | 08/07/2022 | SmPC and PL     |                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IB/0002   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by   | 26/04/2021   | 19/05/2021   | SmPC and PL   | the MAH   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-----------|
| IAIN/0001 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                         | 23/10/2020   | 19/05/2021   | SmPC and PL   |           |